Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination With Capecitabine for Subjects With Recurrent or Treatment Refractory Metastatic Pancreatic Cancer (The RECAP Trial)

NCT01423604 is registered in ClinicalTrials.gov with Incyte Corporation as lead sponsor.

NCT NCT01423604
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01423604 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination With Capecitabine for Subjects With Recurrent or Treatment Refractory Metastatic Pancreatic Cancer (The RECAP Trial)
Lead sponsor
Incyte Corporation
Phase
Phase 2
Overall status
Completed
Start date
July 31, 2011
Completion date
November 30, 2016
Enrollment
136 (actual)
Sites
39

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic cancer